Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing dealMersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology...
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron...
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor...
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
Naarden, The Netherlands, 16 November 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b...
BGV portfolio company Dunad Ltd announces $1.3B strategic collaboration with Novartis on protein degrader therapies
Amsterdam, The Netherlands, 02 November 2021 - BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma today announces that Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of protein degradation therapies,...
Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs
AMSTERDAM, NETHERLANDS - 28 October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the...
VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001
Leiden, The Netherlands, 21 October 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up to €17.5 million from the European Innovation Council (EIC) Accelerator, subject to...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Munich, Germany, October 11, 2021 – CatalYm, today announced an update from the dose escalation part of the ongoing first-in-human trial “GDFather” (GDF-15 Antibody-mediated Effector cell Relocation) investigating its lead product candidate, CTL-002, both in...
Synaffix to Present Key ADC Technology Data on SYNtecan E Linker-Payload at World ADC Conference
Virtual poster presentation shows complete tumor regression and high tolerability of a SYNtecan E™ based ADC SYNtecan E™ linker-payload is a potent exatecan-based, DNA topoisomerase 1 inhibitor developed by Synaffix Data underscores ability of Synaffix’s technologies...
Third ADC with Synaffix’s Technology Enters Clinical Development
AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its...